Andere talen HUTCHMED (China) Limited

Aandelen

HCM

KYG4672N1198

Vertraagde tijd London S.E. Andere beurzen 17:35:21 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
281 ^GBX	-2,43%		-2,43%	-0,71%

25/06	Takeda's geneesmiddel tegen kanker krijgt goedkeuring van Europese Commissie	MT
24/06	Hutchmed China stelt vast dat Takeda EU-goedkeuring heeft gekregen voor Fruzaqla	AN

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Takeda's Cancer Drug Gets European Commission Approval	25/06
Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24/06
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	24/06
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	24/06
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in the Lancet Haematology	18/06
Hutchmed celebrates "promising" results for sovleplenib in China	17/06
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology	17/06
Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology	17/06
Hutchmed (China) begins trial of menin inhibitor HMPL-506	07/06
Hutchmed Begins Phase 1 Trial of Potential Treatment for Acute Myeloid Leukemia	07/06
Hutchmed (China)'a Cancer Drug Phase I Clinical Trial Begins	07/06
HUTCHMED Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China	07/06
HUTCHMED Limited Announces Results from FRUTIGA, HUTCHMED's Phase III Trial of Fruquintinib in Combination with Paclitaxel for the Treatment of Second-Line Advanced Gastric Cancer	03/06
HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine	03/06
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology	24/05
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be presented at the upcoming EHA2024 Congress	20/05
Hutchmed (China) Chairman Resigns, Successor Named	20/05
Hutchmed China Simon To leaves role, succeeded by Dan Eldar	17/05
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor	17/05
HUTCHMED Limited Announces Executive Changes	17/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen HUTCHMED (China) Limited

Aandelen

HCM

KYG4672N1198

Andere talen

Filters